Go to the page content
Other

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Locations

France, Greece, Italy, Spain, United Kingdom, United States

Start date

10/01/2025

Identifiers

Trial ID NN7535-7822,
NCT number NCT06609226,
Eudract number Not Available

Summary

Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.

Trial Overview:

Condition

Sickle Cell Disease, Thalassemia

Treatment

DRUG: Etavopivat A

DRUG: Etavopivat B

Study type

INTERVENTIONAL

Trial duration

Jan 10 2025 - Nov 30 2029

Participants

325

Phase

III

Are you eligible?

Gender

Male and female

Age

Not Available

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.